BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 10955783)

  • 1. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
    Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
    Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
    de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
    Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
    Colnot DR; Roos JC; de Bree R; Wilhelm AJ; Kummer JA; Hanft G; Heider KH; Stehle G; Snow GB; van Dongen GA
    Cancer Immunol Immunother; 2003 Sep; 52(9):576-82. PubMed ID: 14627130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer.
    Koppe M; Schaijk Fv; Roos J; Leeuwen Pv; Heider KH; Kuthan H; Bleichrodt R
    Cancer Biother Radiopharm; 2004 Dec; 19(6):720-9. PubMed ID: 15665619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.
    Verel I; Heider KH; Siegmund M; Ostermann E; Patzelt E; Sproll M; Snow GB; Adolf GR; van Dongen GA
    Int J Cancer; 2002 May; 99(3):396-402. PubMed ID: 11992408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer.
    de Bree R; Roos JC; Quak JJ; den Hollander W; Wilhelm AJ; van Lingen A; Snow GB; Dongen GA
    Clin Cancer Res; 1995 Mar; 1(3):277-86. PubMed ID: 9815983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio.
    Sandström K; Haylock AK; Spiegelberg D; Qvarnström F; Wester K; Nestor M
    Int J Oncol; 2012 May; 40(5):1525-32. PubMed ID: 22307465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD44v6 expressed in head and neck squamous cell carcinoma: preclinical characterization of an 111In-labeled monoclonal antibody.
    Sandström K; Nestor M; Ekberg T; Engström M; Anniko M; Lundqvist H
    Tumour Biol; 2008; 29(3):137-44. PubMed ID: 18612218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma.
    Riechelmann H; Sauter A; Golze W; Hanft G; Schroen C; Hoermann K; Erhardt T; Gronau S
    Oral Oncol; 2008 Sep; 44(9):823-9. PubMed ID: 18203652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck.
    Schrijvers AH; Quak JJ; Uyterlinde AM; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Cancer Res; 1993 Sep; 53(18):4383-90. PubMed ID: 8364934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
    Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
    Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
    Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
    Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunodiagnosis of lymph node metastases in head and neck cancer.
    de Bree R; Roos JC; Verel I; van Dongen GA; Snow GB
    Oral Dis; 2003 Sep; 9(5):241-8. PubMed ID: 14628891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma.
    Haylock AK; Spiegelberg D; Mortensen AC; Selvaraju RK; Nilvebrant J; Eriksson O; Tolmachev V; Nestor MV
    Int J Oncol; 2016 Feb; 48(2):461-70. PubMed ID: 26676731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
    Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
    Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical imaging of head and neck cancer with technetium-99m-labeled monoclonal antibody E48 IgG or F(ab')2.
    de Bree R; Roos JC; Quak JJ; den Hollander W; van den Brekel MW; van der Wal JE; Tobi H; Snow GB; van Dongen GA
    J Nucl Med; 1994 May; 35(5):775-83. PubMed ID: 8176458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform.
    Van Hal NL; Van Dongen GA; Rood-Knippels EM; Van Der Valk P; Snow GB; Brakenhoff RH
    Int J Cancer; 1996 Nov; 68(4):520-7. PubMed ID: 8945625
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.